| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 10.488 µM (XOD)[1]
7,8,3′,4′-Tetrahydroxyflavone targets xanthine oxidase (XOD), a key enzyme in purine metabolism that catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid. It is a potent XOD inhibitor with an IC50 of 10.488 µM. By inhibiting XOD, the compound reduces uric acid production. |
|---|---|
| ln Vitro |
7,8,3′,4′-Tetrahydroxyflavone demonstrates potent in vitro xanthine oxidase inhibitory activity with an IC50 of 10.488 µM. The compound is a flavonoid. These in vitro findings confirm the compound's potent XOD inhibition.
|
| ln Vivo |
In vivo activity data for 7,8,3′,4′-Tetrahydroxyflavone are not extensively documented. Its potent XOD inhibitory activity suggests potential in vivo efficacy for reducing uric acid levels in hyperuricemia and gout models. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for 7,8,3′,4′-Tetrahydroxyflavone involves measuring its inhibition of xanthine oxidase (XOD) activity. Xanthine oxidase is incubated with xanthine as a substrate, and the formation of uric acid is monitored spectrophotometrically at 295 nm. 7,8,3′,4′-Tetrahydroxyflavone is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for 7,8,3′,4′-Tetrahydroxyflavone typically use cell lines to assess its effects on uric acid production. Cells are treated with the compound at various concentrations. Uric acid levels in the medium are measured. The compound's ability to reduce uric acid production is quantified.
|
| Animal Protocol |
In vivo animal experiments for 7,8,3′,4′-Tetrahydroxyflavone are not extensively documented. As a xanthine oxidase inhibitor, standard in vivo studies would involve animal models of hyperuricemia. The compound would be administered via oral or parenteral routes. Serum uric acid levels would be measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7,8,3′,4′-Tetrahydroxyflavone are not extensively documented. As a flavonoid, the compound is expected to have moderate bioavailability. Its tetrahydroxyflavone structure may influence its absorption, distribution, metabolism, and excretion. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 7,8,3′,4′-Tetrahydroxyflavone are not extensively available. As a flavonoid, it is generally considered to have a favorable safety profile. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
2-(3,4-Dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-one belongs to the flavonoid class of compounds. It is the conjugate acid of 3',4',8-trihydroxyflavone-7-ol salt. It has been reported that 7,8,3',4'-tetrahydroxyflavone is found in Acacia confusa, but relevant data are unclear.
7,8,3′,4′-Tetrahydroxyflavone (compound 2) is a potent xanthine oxidase inhibitor with an IC50 of 10.488 µM. It is a flavonoid with potential applications in research on hyperuricemia and gout. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C15H10O6
|
|---|---|
| Molecular Weight |
286.24
|
| Exact Mass |
286.048
|
| CAS # |
3440-24-2
|
| PubChem CID |
688798
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.654g/cm3
|
| Boiling Point |
618.9ºC at 760 mmHg
|
| Flash Point |
240.6ºC
|
| Index of Refraction |
1.767
|
| Source |
Originated from plants: Leguminosae Acacia confusa Merr.
|
| LogP |
2.282
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
447
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C(=C(C=C3)O)O)O)O
|
| InChi Key |
ARYCMKPCDNHQCL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O6/c16-9-3-1-7(5-12(9)19)13-6-11(18)8-2-4-10(17)14(20)15(8)21-13/h1-6,16-17,19-20H
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-7,8-dihydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~200 mg/mL (~698.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (17.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (17.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
